Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CCR8 monoclonal antibody BAY3375968

A human immunoglobulin G1 (IgG1) afucosylated monoclonal antibody against C-C-chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CCR8 monoclonal antibody BAY3375968 targets, binds to and blocks the activity of CCR8 on CCR8-positive tumor-infiltrating regulatory T cells (Tregs) in the tumor microenvironment (TME) and prevents chemokine ligand 1 (CCL1)-CCR8-mediated signaling. BAY3375968 eliminates CCR8-positive Tregs via the induction of Fc-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP), thereby depleting CCR8-positive Tregs. This may reactivate antitumor immune responses. CCR8 is specifically expressed on activated tumor-infiltrating Tregs in multiple types of cancer and plays a key role in immunosuppression. High expression is correlated with poor prognosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:BAY 3375968
BAY-3375968
BAY3375968
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search